IMAB
Price
$1.80
Change
+$0.04 (+2.27%)
Updated
May 3, 9:17 AM EST
26 days until earnings call
RLAY
Price
$6.87
Change
-$0.21 (-2.97%)
Updated
May 3, 11:08 AM EST
96 days until earnings call
Ad is loading...

Analysis and predictions IMAB vs RLAY

Header iconIMAB vs RLAY Comparison
Open Charts IMAB vs RLAYBanner chart's image
I-MAB
Price$1.80
Change+$0.04 (+2.27%)
Volume$200
CapitalizationN/A
Relay Therapeutics
Price$6.87
Change-$0.21 (-2.97%)
Volume$1.3K
CapitalizationN/A
View a ticker or compare two or three
IMAB vs RLAY Comparison Chart

Loading...

IMABDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RLAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
IMAB vs. RLAY commentary
May 03, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMAB is a Hold and RLAY is a Hold.

COMPARISON
Comparison
May 03, 2024
Stock price -- (IMAB: $1.76 vs. RLAY: $7.08)
Brand notoriety: IMAB and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMAB: 36% vs. RLAY: 63%
Market capitalization -- IMAB: $142.03M vs. RLAY: $938.25M
IMAB [@Biotechnology] is valued at $142.03M. RLAY’s [@Biotechnology] market capitalization is $938.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $559.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMAB’s FA Score shows that 0 FA rating(s) are green whileRLAY’s FA Score has 1 green FA rating(s).

  • IMAB’s FA Score: 0 green, 5 red.
  • RLAY’s FA Score: 1 green, 4 red.
According to our system of comparison, RLAY is a better buy in the long-term than IMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMAB’s TA Score shows that 3 TA indicator(s) are bullish while RLAY’s TA Score has 5 bullish TA indicator(s).

  • IMAB’s TA Score: 3 bullish, 5 bearish.
  • RLAY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RLAY is a better buy in the short-term than IMAB.

Price Growth

IMAB (@Biotechnology) experienced а -2.49% price change this week, while RLAY (@Biotechnology) price change was +15.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.32%. For the same industry, the average monthly price growth was -0.52%, and the average quarterly price growth was +1244.27%.

Reported Earning Dates

IMAB is expected to report earnings on Aug 27, 2024.

RLAY is expected to report earnings on Aug 07, 2024.

Industries' Descriptions

@Biotechnology (+5.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for IMAB with price predictions.
OPEN
A.I.dvisor published
a Summary for RLAY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
RLAY($938M) has a higher market cap than IMAB($142M). IMAB YTD gains are higher at: -7.105 vs. RLAY (-35.695).
IMABRLAYIMAB / RLAY
Capitalization142M938M15%
EBITDAN/AN/A-
Gain YTD-7.105-35.69520%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
IMABRLAY
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
IMABDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RLAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MNREX12.730.22
+1.76%
Manning & Napier Real Estate S
PAIGX17.430.27
+1.57%
T. Rowe Price International Value Eq Adv
GTSFX35.230.47
+1.35%
Invesco Small Cap Growth R6
RPXIX25.780.33
+1.30%
RiverPark Large Growth Institutional
PYCGX26.420.17
+0.65%
Pioneer Mid Cap Value Y

IMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMAB has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IMAB jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
N/A
VCYT - IMAB
43%
Loosely correlated
+0.30%
RLAY - IMAB
42%
Loosely correlated
+6.31%
NTLA - IMAB
39%
Loosely correlated
+3.42%
DNA - IMAB
39%
Loosely correlated
+2.26%
BEAM - IMAB
39%
Loosely correlated
+4.51%
More

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with PRME. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
+6.31%
PRME - RLAY
55%
Loosely correlated
+6.45%
NTLA - RLAY
52%
Loosely correlated
+3.42%
XNCR - RLAY
49%
Loosely correlated
-1.25%
ADPT - RLAY
49%
Loosely correlated
+5.02%
BEAM - RLAY
49%
Loosely correlated
+4.51%
More